Compare Twist Bioscience Corp (TWST) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs VNET Group Inc — how do they compare? Twist Bioscience Corp trades at $159.78 (market cap $10.08B), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: Twist Bioscience Corp is far larger — about 6.9× VNET Group Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and VNET Group Inc for 16 Days on average.
| TWST | VNET | |
|---|---|---|
Market Cap | $10.08B | $1.47B |
Volume | 4,229,037 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $205.00 | $14.03 |
52-Week Low | $25.45 | $5.13 |
Typical Hold Time | 27 Days | 16 Days |
Enterprise Value | $10.01B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
VNET trades at $5.17, down 4.08% today, near 52-week lows. The stock is technically bearish with weak moving averages. Fundamentally, revenue grew to $9.95B in 2025, but net losses persist with a -22.18% margin. Recent news includes a strategic investment closing and a cooperation agreement with CATL.
Outlook remains challenged by losses and high leverage, though analyst consensus is moderately bullish. Key risks include negative cash flow and execution uncertainty. The stock offers speculative appeal if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
